SOURCE: Smartec Holdings Inc.

November 30, 2007 12:11 ET

Smartec Acquires Technology for Detecting Early Stage Cancers

RENO, NV--(Marketwire - November 30, 2007) - Smartec Holdings Inc. (OTCBB: SMHN) (the "Company" or "Smartec") is pleased to announce that it has entered into a binding Asset Purchase Agreement dated November 27, 2007 with two private companies in respect to the purchase of a proprietary technology for the generation of monoclonal antibodies against various antigens in consideration for 25,638,400 shares in the common stock of the Company. The acquisition is expected to close on or before January 15, 2008.

The acquired technology is very unique in that it has generated highly specific antibodies (known as monoclonal antibodies or Mabs) against ovarian cancer, prostate cancer and melanoma. The Company plans to generate Mabs against colorectal cancer, breast cancer, lung cancer and pancreatic cancer.

The Company is now poised to begin the approval process for developing a screening test for ovarian cancer and a diagnostic test for aggressive prostate cancer. The technology would allow the Company to use its unique antibodies not only for detection of early stage, curable cancers, but also for imaging of the spread of cancer and developing highly specific treatments of the disease.

The acquisition represents the first significant step for the Company as it transitions from its current business into the exciting area of cancer detection and therapy.

For further information, please contact:

Investor Relations
888-299-1989
info@mabcure.com

This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, statements as to the intended uses of the proceeds received from the private placement.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.

Contact Information

  • For further information, please contact:

    Investor Relations
    888-299-1989
    Email Contact